Latigo Biotherapeutics appoints Todd Smith to its board
Latigo Biotherapeutics appointed Todd Smith as an independent director to its board of directors. Smith, the CEO of Corium, brings over three decades of executive leadership and commercial experience to the clinical-stage company focused on non-opioid pain medicines.
*this image is generated using AI for illustrative purposes only.
Latigo Biotherapeutics, Inc. has appointed Todd Smith as an independent director on its board of directors. The appointment brings over three decades of executive leadership and commercial experience to the clinical-stage biopharmaceutical company focused on non-opioid pain medicines.
Smith is the chief executive officer (CEO) of Corium, a commercial-stage biopharmaceutical company focused on neuroscience. His background includes extensive expertise in commercialization, business development, and corporate strategy across the biotechnology and pharmaceutical industries.
Executive Background
Smith's career includes serving as CEO of Valinor Pharma, Iroko Pharmaceuticals, Zyla Life Sciences, and Assertio Therapeutics. Earlier, he was chief commercial officer (CCO) and head of business development at Horizon Therapeutics and CCO at Tolmar Pharmaceuticals. He also held commercial leadership roles at Abbott Labs and Fenwal.
| Role | Company |
|---|---|
| CEO | Corium |
| CEO | Valinor Pharma |
| CEO | Iroko Pharmaceuticals |
| CEO | Zyla Life Sciences |
| CEO | Assertio Therapeutics |
| CCO | Horizon Therapeutics |
| CCO | Tolmar Pharmaceuticals |
Smith currently serves on the boards of BVI Medical, Quetzal Therapeutics, and Corium. He earned a B.A. in political science from Norwich University.
Strategic Implications
Latigo's CEO, Nima Farzan, highlighted Smith's commercial expertise with launching innovative biopharmaceutical products as timely for the company. Tim Walbert, chair of Latigo's board, noted that Smith's experience in bringing medicines to patients and building organizations will be invaluable.
Latigo Biotherapeutics is a private clinical-stage company developing non-opioid pain medicines. Its lead program is LTG-001, an oral, selective NaV1.8 inhibitor for acute pain. The company is supported by investors including Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital.
How might Todd Smith's commercialization experience influence Latigo's strategy for the upcoming launch of LTG-001?
Could this appointment signal an acceleration in Latigo's timeline for advancing its non-opioid pain pipeline?
Will Smith's role on the board lead to potential partnerships or collaborations with other companies in his network?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
